<DOC>
	<DOC>NCT00324116</DOC>
	<brief_summary>To evaluate the efficacy, based on the best-corrected visual acuity (using the ETDRS chart), of a 0.3 mg/eye pegaptanib sodium intravitreous injection given every 6 weeks for 54 weeks in patients with exudative age-related macular degeneration and evidence of recent onset, subfoveal and/or juxtafoveal choroidal neovascularization.</brief_summary>
	<brief_title>Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Clinical and angiographic evidence of juxtafoveal or subfoveal choroidal neovascularization secondary to AMD with a total lesion size of less than 2 MPS disc areas Bestcorrected visual acuity in the study eye greater than 54 letters (ETDRS) Women must be using 2 forms of effective contraception Adequate hematological, renal and liver functions Any atrophy or fibrosis; any retinal hemorrhage measuring more than 1 disc area Any extrafoveal choroidal neovascularization Any intraocular surgery or thermal laser to the study eye within 3 months of enrollment Previous or concomitant therapy for AMD including PDT with verteporfin (Visudyne) or subfoveal/nonfoveal thermal laser therapy, transpupillary thermotherapy, external beam radiation, submacular surgery. Presence of other causes of choroidal neovascularization, including pathological myopia, the ocular histoplasmosis syndrome, angioid streaks, choroidal rupture and multifocal choroiditis</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>